Tokyo

The joining of two of the largest pharmaceutical brands in Japan provided the opportunity to create a unified brand vision, mission and values - along with a visual brand and logo that looked to the past and the strength of the brands - while also forging a new future identity moving forward.

With a new therapeutic option for those suffering from epileptic seizures that had high future potential with current, anticipated and potential indications, a name needed to be created that would find itself appropriate for all stages of the product lifecycle. This is where our ability to tap into the extensive experience and ability of our market research team came into play.

Aegerion entrusted us to define the brand direction for its first asset. As an orphan drug and one with a variety of potential future indications, the Addison Whitney teams developed the target audience profile and then created the branding elements with a firm eye on how to best serve these audiences.